{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:25:44Z","timestamp":1761863144927},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,8,2]],"date-time":"2012-08-02T00:00:00Z","timestamp":1343865600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1007\/s11239-012-0782-y","type":"journal-article","created":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:50:39Z","timestamp":1343782239000},"page":"499-505","source":"Crossref","is-referenced-by-count":6,"title":["Angiographic and platelet reactivity outcomes with prasugrel 60\u00a0mg pretreatment and clopidogrel 600\u00a0mg pretreatment in primary percutaneous coronary intervention"],"prefix":"10.1007","volume":"34","author":[{"given":"Yiding","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bee-Choo","family":"Tai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winnie","family":"Sia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian-Hui","family":"Phua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Richards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Low","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koo-Hui","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swee-Guan","family":"Teo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiong-Beng","family":"Sim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Hang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew T.","family":"Roe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiong-Cheng","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huay-Cheem","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark Y.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,8,2]]},"reference":[{"issue":"10","key":"782_CR1","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1001\/jama.294.10.1224","volume":"294","author":"MS Sabatine","year":"2005","unstructured":"Sabatine MS, Cannon CP, Gibson CM et al (2005) Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics. The PCI-CLARITY study. J Am Med Assoc 294(10):1224\u20131232","journal-title":"J Am Med Assoc"},{"key":"782_CR2","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1160\/TH05-03-0208","volume":"94","author":"M Hasegawa","year":"2005","unstructured":"Hasegawa M, Sugidachi A, Ogawa T et al (2005) Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor. Thromb Haemost 94:593\u2013598","journal-title":"Thromb Haemost"},{"key":"782_CR3","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0140-6736(09)60441-4","volume":"373","author":"G Montalescot","year":"2009","unstructured":"Montalescot G, Wiviott SD, Braunwald E et al (2009) Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON\u2013TIMI 38): double-blind, randomised controlled trial. Lancet 373:723\u2013731","journal-title":"Lancet"},{"key":"782_CR4","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.jacc.2011.06.044","volume":"58","author":"G Patti","year":"2011","unstructured":"Patti G, Barczi G, Orlic D et al (2011) Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) randomized study. J Am Coll Cardiol 58:1592\u20131599","journal-title":"J Am Coll Cardiol"},{"key":"782_CR5","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.clinthera.2010.02.015","volume":"32","author":"DS Small","year":"2010","unstructured":"Small DS, Payne CD, Kothare P et al (2010) Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30\u00a0mg and clopidogrel 300\u00a0mg in healthy Chinese and white volunteers: an open-label trial. Clin Ther 32:365\u2013379","journal-title":"Clin Ther"},{"key":"782_CR6","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/j.1538-7836.2007.02421.x","volume":"5","author":"JW Werkum van","year":"2007","unstructured":"van Werkum JW, van der Stelt CA, Seesing TH et al (2007) The flow cytometric VASP assay can be used to determine the effectiveness of clopidogrel in patients treated with abciximab. J Thromb Haemost 5:881\u2013883","journal-title":"J Thromb Haemost"},{"key":"782_CR7","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1161\/01.CIR.93.5.879","volume":"93","author":"CM Gibson","year":"1996","unstructured":"Gibson CM, Cannon CP, Daley WL et al (1996) TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 93:879\u2013888","journal-title":"Circulation"},{"key":"782_CR8","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","volume":"56","author":"L Bonello","year":"2010","unstructured":"Bonello L, Tantry US, Marcucci R et al (2010) Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56:919\u2013933","journal-title":"J Am Coll Cardiol"},{"key":"782_CR9","doi-asserted-by":"crossref","unstructured":"Chan MY, Sun JL, Wang TY et al (2010) Patterns of discharge antiplatelet therapy and late outcomes among 8,582 patients with bleeding during acute coronary syndrome: a pooled analysis from PURSUIT, PARAGON-A, PARAGON-B, and SYNERGY. Am Heart J 160:1056\u20131064, 1064. e2","DOI":"10.1016\/j.ahj.2010.09.001"},{"key":"782_CR10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1160\/TH09-07-0482","volume":"103","author":"G Montalescot","year":"2010","unstructured":"Montalescot G, Sideris G, Cohen R et al (2010) Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thromb Haemost 103:213\u2013223","journal-title":"Thromb Haemost"},{"key":"782_CR11","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1160\/TH10-11-0715","volume":"105","author":"H Fernando","year":"2011","unstructured":"Fernando H, Dart AM, Peter K et al (2011) Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy. Thromb Haemost 105:933\u2013944","journal-title":"Thromb Haemost"},{"key":"782_CR12","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.jacc.2009.05.025","volume":"54","author":"M O\u2019Donoghue","year":"2009","unstructured":"O\u2019Donoghue M, Antman EM, Braunwald E et al (2009) The efficacy and safety of prasugrel with and without a glycoprotein IIb\/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON\u2013TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. J Am Coll Cardiol 54:678\u2013685","journal-title":"J Am Coll Cardiol"},{"key":"782_CR13","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1161\/CIRCULATIONAHA.107.740324","volume":"116","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Trenk D, Frelinger AL et al (2007) Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 116:2923\u20132932","journal-title":"Circulation"},{"key":"782_CR14","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jacc.2011.04.017","volume":"58","author":"L Bonello","year":"2011","unstructured":"Bonello L, Pansieri M, Mancini J et al (2011) High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol 58:467\u2013473","journal-title":"J Am Coll Cardiol"},{"key":"782_CR15","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1177\/0091270009355161","volume":"50","author":"M Man","year":"2010","unstructured":"Man M, Farmen M, Dumaual C et al (2010) Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J Clin Pharmacol 50:929\u2013940","journal-title":"J Clin Pharmacol"},{"key":"782_CR16","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2217\/pgs.12.24","volume":"13","author":"MY Chan","year":"2012","unstructured":"Chan MY, Tan K, Tan H-C et al (2012) Functional significance and differential prevalence of CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects. Pharmacogenomics 13:533\u2013542","journal-title":"Pharmacogenomics"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-012-0782-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-012-0782-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-012-0782-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T06:34:01Z","timestamp":1562049241000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-012-0782-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,2]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["782"],"URL":"https:\/\/doi.org\/10.1007\/s11239-012-0782-y","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,2]]}}}